We clarified the signaling cascade involved in hypoxia-mediated cisplatin resistance in NSCLC and identified eIF5A2 as a new therapeutic target to support cisplatin efficacy. The gene discussed is EIF5A2; the disease is non-small cell lung carcinoma.